Oncology
Showing 21-40 of 95 Results
-
James C. Dickerson, MD MS
Clinical Assistant Professor, Medicine - Oncology
BioDr. Dickerson is a medical oncologist in the Division of Medical Oncology at Stanford University School of Medicine, specializing in the care of patients with breast cancer. In addition to seeing patients in the clinic, he researches how health policy, data science, and emerging technologies can improve cancer care delivery. His research group focuses on three core objectives: (1) developing financially sustainable cancer care programs, (2) analyzing large clinical and administrative datasets to identify gaps where policy can improve equity and outcomes, and (3) conducting clinical and implementation research to determine the most effective ways to deliver high-quality, evidence-based oncology care.
Across these objectives, Dr. Dickerson integrates traditional real-world data analytics with modern natural language processing approaches, including large language models, to study cancer care delivery. His group develops and applies LLM-based tools to improve the extraction, structuring, and interpretation of complex clinical information from electronic health records, to enhance clinical decision-making, care coordination, and health policy evaluation.
Dr. Dickerson received his undergraduate degree from Vanderbilt University and graduated magna cum laude from the University of Mississippi Medical Center. He completed his internship and residency in Internal Medicine at Stanford University, followed by fellowship training in Hematology and Oncology. During his fellowship, Dr. Dickerson earned a Master’s degree in Health Policy and completed post-doctoral research in the Department of Health Policy. -
Milana V. Dolezal, MD, MSci
Clinical Associate Professor, Medicine - Oncology
BioDr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology.
She strives to work with patients to develop care plans that are comprehensive and personalized achieve the best possible outcomes and quality of life.
Dr. Dolezal also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech.
She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients’ adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications.
She also co-authored the chapter “Progression from Hormone-Dependent to Hormone-Independent Breast Cancer” in the textbook Hormones, Genes and Cancer published by Oxford University Press.
Dr. Dolezal has made presentations to her peers at meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Organisation. -
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine, Emeritus
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Kristen N Ganjoo
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsGiant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Neel K. Gupta
Clinical Associate Professor, Medicine - Oncology
Current Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.
-
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Thomas Holden, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Holden is a board-certified, fellowship-trained medical oncologist. He is a Clinical Assistant Professor at Stanford University School of Medicine.
He specializes in care for people with gastrointestinal cancer including those of the colon, rectum, esophagus, liver, pancreas, and stomach. Dr. Holden works closely with patients to prepare personalized, comprehensive, and compassionate care plans that optimize healing and quality of life.
Dr. Holden has conducted research into a wide range of subjects. He co-developed and established a multi-center trial investigating a new treatment regimen for gastric cancer. He has studied use of a fitness tracker to assess activity levels and toxicities in patients with colorectal cancer. He also has written invited commentary on the rapidly advancing field of genetic testing as well as a review on recent updates on the treatment of early-stage rectal cancer.
He has published his research findings in articles in peer-reviewed journals including JAMA, the Journal of Clinical Oncology, Cortex, and elsewhere. He has made poster presentations to his peers at meetings including the ASCO Gastrointestinal Cancers symposium and House Staff Quality Improvement and Patient Safety Conference, a meeting held annually at Thomas Jefferson University.
Dr. Holden has volunteered his time and expertise to help improve access to health care for homeless and underserved populations.
In his free time, he runs, reads, plays the acoustic guitar, and travels. -
Sandra Horning
Professor of Medicine, Emerita
Current Research and Scholarly InterestsClinical Interests: Hodgkin's disease and non-Hodgkin's lymphoma. Research Interests: clinical trials in Hodgkin's disease and malignant lymphoma including high dose therapy and autografting, complications of cytotoxic therapy, novel therapeutics, and clinicopathologic correlations.
-
Robert Hsieh
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioRobert W. Hsieh, M.D. Ph.D. is a medical oncologist who specializes in the treatment of prostate cancer, bladder cancer, kidney (renal) cancer and testicular cancer as a member of Stanford's multi-disciplinary Urologic Cancer Program. Dr. Hsieh obtained his M.D. and Ph.D. degrees at the University of Chicago (Pritzker School of Medicine) and subsequently came to Stanford to complete his Internal Medicine residency and Hematology and Oncology fellowship training (with a clinical focus on genitourinary cancers).
Dr. Hsieh has also had extensive experience in basic lab research (cancer stem cells, target identification and validation, pre-clinical drug discovery) having done post-doctoral work in the Clarke Lab in the Institute for Stem Cell Biology and Regenerative Medicine. He is currently involved in early phase clinical trials in immuno-oncology in industry. -
Haruka Itakura, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Haruka Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine, a data scientist, and a practicing breast medical oncologist at the Stanford Women’s Cancer Center. She is board-certified in Oncology, Clinical Informatics, Hematology, and Internal Medicine. Her research mission is to drive medical advances at the intersection of cancer and data science, applying state-of-the-art machine learning/artificial intelligence (AI) techniques to extract clinically actionable knowledge from heterogeneous multi-scale cancer data to improve patient outcomes. Her ongoing research to develop robust methodologies and apply cutting-edge techniques to analyze complex cancer big data was catapulted by an NIH K01 Career Development Award in Biomedical Big Data Science after obtaining a PhD in Biomedical Informatics at Stanford University. Her cancer research focuses on extracting radiomic (pixel-level quantitative imaging) features of tumors from medical imaging studies and applying machine learning frameworks, including radiogenomic approaches, for the integrative analysis of heterogeneous, multiomic (e.g., radiomic, genomic, transcriptomic) data to accelerate discoveries in cancer diagnostics and therapeutics. Her current projects include data science/AI-powered prediction modeling of survival, treatment response, cancer recurrence, and metastasis in different cancer subtypes; detection of occult invasive breast cancer; and identification of novel therapeutic targets. Her goal is to translate her research findings back to the clinical setting for the benefit of patients with difficult-to-treat cancers.
-
Charlotte D. Jacobs M.D.
Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsClinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.
-
Hanlee P. Ji
Professor of Medicine (Oncology) and, by courtesy of Electrical Engineering
Current Research and Scholarly InterestsCancer genomics and genetics, translational applications of next generation sequencing technologies, development of molecular signatures as prognostic and predictive biomarkers in oncology, primary genomic and proteomic technology development, cancer rearrangements, genome sequencing, big data analysis
-
Esther M. John
Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)
Current Research and Scholarly InterestsDr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race and ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.
As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:
- the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
- the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 African American, Hispanic, and non-Hispanic White women that investigated the role of modifiable lifestyle factors and other risk factors;
- the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic White populations in the context of genetic admixture;
- the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in minoritized racial and ethnic populations;
- the Northern California site of the WECARE Study that investigates risk factors for second primary contralateral breast cancer;
- the Second Primary Breast Cancer Disparities Study, a pooled analysis of risk factors for contralateral and ipsilateral second primary breast cancer in a diverse population;
- the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.
These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in minoritized racial and ethnic populations.
Dr. John is a founding PI of the LEGACY Girls Study, a prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer.
In 2023, Dr. John joined the Stanford investigator team of the MOSAAIC (The Multiethnic Observational Study in American Asian and Pacific Islander Communities) Study, a five-center study to improve health of American Asian, Native Hawaiian, and Pacific Islander populations.
